Monitoring a virus biomarker after stem cell transplant
Part of Immune system & allergy, Infections clinical trials.
This trial checks if measuring a specific virus marker in your blood after a stem cell transplant can help predict or prevent transplant complications. You would have extra blood tests to guide your care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are scheduled to have a stem cell transplant from a donor (allogeneic)
- You can understand the study and sign a consent form
- You are willing to take part voluntarily
- You are not pregnant or breastfeeding
- You do not have severe memory or thinking problems that would prevent blood draws
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
This trial is for patients with blood disorders who are getting a half-matched stem cell transplant (from a family donor). It tests a new way to measure your immune system's response to two common viruses (CMV and EBV) after transplant, which may help doctors prevent or treat infections better.
This trial tests whether a special antibody treatment (CMV-specific immunoglobulin) can prevent CMV infections in children who have had a stem cell transplant from a donor. It may help protect your child’s immune system during recovery.
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.